Skip to main content
Clinical Trials/NCT05048355
NCT05048355CompletedNot Applicable

Metabolic Cost of Level Ground Walking With Passive vs. Powered Microprocessor Controlled Knees for Higher Active TF Amputees

Össur Ehf4 sites in 2 countries15 target enrollmentStarted: May 26, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
15
Locations
4
Primary Endpoint
Metabolic cost

Study Overview

Brief Summary

This study is conducted to evaluate the efficacy of the Power Knee Mainstream Dynamic compared to passive microprocessor-controlled knees (MPKs) regarding metabolic cost for high active transfemoral amputees.The test is of a single group repeated measures crossover design. The primary endpoint is the difference in MET/HRI-VO2 index between conditions. Subjects are measured on their prescribed device at visit 1, be fitted to the PKM which they wear as their primary prosthesis for one week before coming for visit 2 and being measured again on the PKM.

Detailed Description

The metabolic cost of ambulation for individuals living with a lower limb amputation is significantly increased compared to able-bodied individuals. Individuals living with transfemoral amputation have shown up to 65% more exertion to generate half the ambulation speed of able-bodied individuals.

The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face. This study aims to evaluate this indirectly by measuring the heart rate during level ground walking on the Power Knee Mainstream - Dynamic compared to a passive MPK.

Previous studies reported in the literature on previous versions of the Power Knee have shown that it provides active flexion and extension during walking2, 3, 4 and more symmetric gait5 compared to passive microprocessor-controlled knees (MPKs). By providing increased symmetry and active swing during level ground walking the knee is meant to lower the effort needed by the transfemoral prosthesis user to swing the leg forward and thereby lower the metabolic cost of level ground walking.

This underpins the hypothesis being tested in this investigation, that the Power Knee Mainstream - Dynamic enables the user to walk with less metabolic cost compared to passive MPKs.

A pilot investigation that was conducted with 5 subjects indicated that the Power Knee Mainstream - Dynamic enabled users to walk on level ground with less metabolic cost compared to passive MPKs, however the difference did not reach statistical significance. The same study procedure will be used in this study with sufficient sample size to achieve the statistical power needed, which was determined in a power analysis using data form the pilot study mentioned above.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 50Kg< body weight < 116Kg
  • Cognitive ability to understand all instructions and questionnaires in the study;
  • Higher active unilateral trans-femoral amputees
  • Allows for 37mm knee center height to dome of pyramid alignment to allow for symmetrical knee height to sound side
  • Willing and able to participate in the study and follow the protocol
  • Comfortable and stable socket fit
  • No socket issues/changes in the last 6 weeks
  • No residual limb pain affecting functional ability
  • Users with at least 6 months experience on a prosthesis

Exclusion Criteria

  • Hip disarticulation amputees
  • Bilateral amputees
  • Users with Osseointegrated prosthesis
  • Users with co-morbidities in the contra-lateral limb, which significantly affect their functional mobility
  • Users taking beta-adrenergic blocking agents (beta blockers) or other medication for heart rate control e.g. Verapamil & Digoxin.

Outcomes

Primary Outcomes

Metabolic cost

Time Frame: 1 week

MET/HRI-VO2 index

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Össur Ehf
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials